New products (and one-offs) drive guidance upgrade
13/08/19 -"Solid momentum of the new drugs, Ozempic and Saxenda, helped Novo Nordisk achieve another healthy quarterly performance, while the insulin woes only furthered. The Biopharmaceuticals clocked growth ..."
Pages
73
Language
English
Published on
13/08/19
You may also be interested by these reports :
25/04/24
The Q1 results topped expectations, led by robust performances across all the key segments. While the management maintained its 2024 guidance, an ...
25/04/24
Q1 results surpassed expectations, on the back of a strong showing from immunology drug Dupixent, RSV vaccine Beyfortus and the new launches of ...
24/04/24
The Q1 sales met the street’s expectations, although forex, off-patent drugs’ generic/biosimilar erosion and declining COVID-19 sales adversely ...
24/04/24
Ipsen started 2024 on a positive note with sales ahead of the company-compiled consensus. Double-digit growth was led by Neuroscience, Oncology, and ...